Korro Bio (KRRO) Non-Current Debt (2018 - 2022)
Korro Bio's (KRRO) quarterly Non-Current Debt came in at $4.2 million in Q4 2022, down 70.59% on a YoY basis from $14.2 million in Q4 2021, and down 37.5% quarter-over-quarter from $6.7 million in Q3 2022.
Analysis
Korro Bio (KRRO) Non-Current Debt (2018 - 2022) Analysis & Trends
Korro Bio (KRRO) has reported Non-Current Debt for 5 consecutive years, with $4.2 million the latest figure, recorded in Q4 2022.
- For the quarter ending Q4 2022, Non-Current Debt fell 70.59% year-over-year to $4.2 million; the trailing twelve-month figure through Dec 2022 stood at $4.2 million (down 70.59% YoY), and the FY2022 full-year result was $4.2 million, down 70.59% from the prior year.
- Non-Current Debt eased to $4.2 million in Q4 2022 per KRRO's latest filing, from $6.7 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $15.0 million in Q4 2020 and bottomed at $180000.0 in Q4 2019.
- Historically, Non-Current Debt has averaged $8.9 million across 5 years, with a median of $10.4 million in 2022.
- The sharpest annual moves came in 2020 and 2022: Non-Current Debt surged 8233.33% in 2020, then tumbled 70.59% in 2022.
- Over 5 years, Non-Current Debt stood at $349000.0 in 2018, then tumbled by 48.42% to $180000.0 in 2019, then soared by 8233.33% to $15.0 million in 2020, then slipped by 5.55% to $14.2 million in 2021, then plunged by 70.59% to $4.2 million in 2022.
- According to Business Quant data, Non-Current Debt over the past three periods registered $4.2 million, $6.7 million, and $9.2 million for Q4 2022, Q3 2022, and Q2 2022 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 57.30 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 26.25 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.99 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 591.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 7.29 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Korro Bio | 231.15 Mn | 116.12 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 4.17 Mn |
| Sep 30, 2022 | 6.67 Mn |
| Jun 30, 2022 | 9.17 Mn |
| Mar 31, 2022 | 11.67 Mn |
| Dec 31, 2021 | 14.17 Mn |
| Sep 30, 2021 | 15.00 Mn |
| Jun 30, 2021 | 15.00 Mn |
| Mar 31, 2021 | 15.00 Mn |
| Dec 31, 2020 | 15.00 Mn |
| Dec 31, 2019 | 180,000.00 |
| Sep 30, 2019 | 222,000.00 |
| Dec 31, 2018 | 349,000.00 |